RBR-9qks3pc
Recruiting
未知
Effect of testosterone replacement associated with bariatric surgery in men with obesity: a randomized trial
Hospital e Maternidade São Domingos0 sitesJuly 13, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hospital e Maternidade São Domingos
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Body Mass Index \- BMI \> 35; weighing up to 180 kg; with low testosterone levels (\<350 ng/dl); classified as hypogonadal; who voluntarily agreed to participate in the research, in addition to understanding and consenting to participation through the TCLE (Free and Informed Consent Form)
Exclusion Criteria
- •Interest in fertility in the 6 months following therapy; diagnosis of active prostate or breast cancer; previous diagnosis of prostate cancer, with less than two years of curative treatment; previous diagnosis of breast cancer; severe voiding symptoms, translated through the IPSS score (International Prostatic Symptom Score) \> 19; severe cardiopulmonary disease (eg unstable angina, recent myocardial infarction); personal or family history of thromboembolism; hematocrit above 48%; patients with implanted medical devices such as pacemakers or essential support devices such as monitors
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Study of effects of testosterone replacement therapy in hypogonadal men with type 2 diabetes mellitusCTRI/2019/09/021175Dr Ronak Gandhi
Active, not recruiting
Phase 1
The effect of testosterone replacement threapy in men using opioidsEUCTR2014-004729-42-DKOdense University Hospital, department M40
Active, not recruiting
Phase 1
A clinical trial for the effects of testosterone replacement therapy in male patients with hypogonadism on arterial function markersEUCTR2014-005179-10-GRCharalampos Vlachopoulos24
Completed
Not Applicable
Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivityHypogonadal men with decreased insulin sensitivityNutritional, Metabolic, EndocrineTesticular hypofunctionISRCTN45741714ProStrakan Pharmaceuticals (UK)320
Active, not recruiting
Not Applicable
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520